Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Foghorn Therapeutics Reports Record Collaboration Revenue for Fiscal Year 2024

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
Biotechnology Stock Exchange
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Foghorn Therapeutics announced a substantial increase in collaboration revenue for the fiscal year ending March 7, 2024. The company reported $34.2 million in revenue, a significant jump from the $19.2 million generated in the prior year. This growth highlights the success of Foghorn Therapeutics’ partnerships and underscores its continued momentum in the industry.

March 7, 2024: FHTX Stock Price Increases by 6.26%

On March 7, 2024, FHTX stock closed at $6.79, which was a $0.40 increase from the previous market close, representing a 6.26% rise in the stock price for the day.

FHTX Stock Analysis: Impressive Revenue Growth and Improved Profitability on March 7, 2024

On March 7, 2024, FHTX stock had a strong performance based on the financial data provided by CNN Money. The company reported a total revenue of $19.23 million for the past year, which represented an impressive increase of 1357.77% compared to the previous year. Furthermore, the total revenue for the last quarter was $17.48 million, showing a significant increase of 212.16% since the previous quarter.

Despite the positive revenue growth, FHTX reported a net income of -$108.88 million for the past year and -$14.35 million for the last quarter. Although the net income decreased by 7.46% since the previous year, it increased by 51.35% since the previous quarter. This improvement in net income could be attributed to the company’s efforts to control costs and increase operational efficiency.

In terms of earnings per share (EPS), FHTX reported a negative EPS of -$2.62 for the past year and -$0.34 for the last quarter. However, there was a slight increase of 3.96% in EPS since the previous year and a significant increase of 51.59% since the previous quarter. This improvement in EPS indicates that the company’s profitability is on the rise, which could be a positive sign for investors.

Overall, FHTX stock showed strong performance on March 7, 2024, with significant increases in total revenue, net income, and EPS compared to the previous year and quarter. Investors may view these financial indicators as a positive signal of the company’s growth potential and future profitability.

Tags: FHTX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
SO stock news

Paysafe Reports Strong Financial Results for Q4 2023 and Full Year Focuses on Growth in 2023

Automotive Trading online

Polestar Slashes Prices for Polestar 4 Model in China

Cryptocurrency Stock Market Today

Bitfarms Ambitious Fleet Upgrade Plan for 2024

Recommended

Torrid Holdings Stock

Torrid Holdings Faces Critical Earnings Test

5 months ago
Take-Two Stock

Take-Two Shares in Holding Pattern as Investors Await GTA VI Details

6 months ago
Union Pacific Stock

Union Pacific’s Future Hangs in Balance as Historic Railroad Merger Faces Critical Vote

4 months ago
Biotechnology Markets and money

BioTechnes Quarterly Earnings and Stock Performance Analysis

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Claros Mortgage Trust Secures Financial Flexibility Through Strategic Debt Overhaul

Trending

Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

by SiterGedge
February 7, 2026
0

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which...

Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Potbelly Stock

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success
  • Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com